The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
